GENFLEET-B (02595) Jumps Nearly 5% in Early Trading as GFH276 Gains Clinical Approvals for Multiple Innovative Combination Therapies

Stock News11-04

GENFLEET-B (02595) rose nearly 5% in early trading. As of press time, the stock was up 3.84% at HK$19.48, with a turnover of HK$15.6191 million.

On the news front, GENFLEET-B announced that since the third quarter of this year, multiple innovative combination therapies involving its oral pan-RAS inhibitor GFH276 have received clinical trial approvals from China's CDE, or completed clinical trial filings with Australia's TGA.

The related studies cover first-line and later-line treatment of multiple major RAS-mutant cancer types, with some trials already having enrolled patients across multiple dose levels.

China Merchants Securities issued a research report stating that GFH276's first-in-human data is positive, with a 41% ORR in PDAC and a 14.8% rate of Grade 3 or higher TRAEs being the core highlights. The early efficacy and safety profile demonstrates potential superiority over RMC-6236's comparable data, positioning it as a potential best-in-class global pan-RAS inhibitor.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment